Jonathan Miller
Stock Analyst at Evercore ISI
(1.66)
# 3,470
Out of 4,455 analysts
52
Total ratings
52.1%
Success rate
0.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintained: Buy | $15 | $2.85 | +426.32% | 3 | May 27, 2026 | |
| NKTX Nkarta | Maintained: Buy | $9 | $2.83 | +218.02% | 1 | May 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $74 → $76 | $54.92 | +38.38% | 2 | May 11, 2026 | |
| JANX Janux Therapeutics | Maintained: Buy | $23 → $22 | $14.94 | +47.26% | 5 | May 11, 2026 | |
| TRDA Entrada Therapeutics | Maintained: Buy | $25 | $7.74 | +223.00% | 2 | May 5, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $14 → $16 | $16.68 | -4.08% | 5 | Apr 28, 2026 | |
| ERAS Erasca | Maintained: Buy | $11 → $24 | $16.01 | +49.91% | 2 | Apr 28, 2026 | |
| PMVP PMV Pharmaceuticals | Maintained: Buy | $18 → $4 | $1.19 | +236.13% | 2 | Apr 13, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintained: Buy | $45 → $23 | $11.60 | +98.28% | 4 | Apr 13, 2026 | |
| AURA Aura Biosciences | Maintained: Buy | $13 → $15 | $7.00 | +114.29% | 3 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 → $48 | $24.15 | +98.76% | 3 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 → $13 | $1.68 | +673.81% | 2 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $31.00 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $110 → $19 | $8.00 | +137.50% | 3 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.50 | - | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $4.49 | +33.78% | 1 | Nov 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $14.00 | -14.29% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $6.44 | n/a | 2 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.81 | n/a | 3 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.83 | n/a | 1 | Sep 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $10.39 | n/a | 2 | May 5, 2021 |
Editas Medicine
May 27, 2026
Maintained: Buy
Price Target: $15
Current: $2.85
Upside: +426.32%
Nkarta
May 18, 2026
Maintained: Buy
Price Target: $9
Current: $2.83
Upside: +218.02%
CRISPR Therapeutics AG
May 11, 2026
Maintained: Buy
Price Target: $74 → $76
Current: $54.92
Upside: +38.38%
Janux Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $23 → $22
Current: $14.94
Upside: +47.26%
Entrada Therapeutics
May 5, 2026
Maintained: Buy
Price Target: $25
Current: $7.74
Upside: +223.00%
Intellia Therapeutics
Apr 28, 2026
Maintained: Hold
Price Target: $14 → $16
Current: $16.68
Upside: -4.08%
Erasca
Apr 28, 2026
Maintained: Buy
Price Target: $11 → $24
Current: $16.01
Upside: +49.91%
PMV Pharmaceuticals
Apr 13, 2026
Maintained: Buy
Price Target: $18 → $4
Current: $1.19
Upside: +236.13%
4D Molecular Therapeutics
Apr 13, 2026
Maintained: Buy
Price Target: $45 → $23
Current: $11.60
Upside: +98.28%
Aura Biosciences
Apr 13, 2026
Maintained: Buy
Price Target: $13 → $15
Current: $7.00
Upside: +114.29%
Mar 9, 2026
Reiterated: Buy
Price Target: $33 → $48
Current: $24.15
Upside: +98.76%
Mar 9, 2026
Maintained: Buy
Price Target: $1 → $13
Current: $1.68
Upside: +673.81%
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $31.00
Upside: -
Feb 25, 2026
Maintained: Buy
Price Target: $110 → $19
Current: $8.00
Upside: +137.50%
Jan 26, 2026
Maintained: Buy
Price Target: n/a
Current: $4.50
Upside: -
Nov 28, 2025
Maintained: Buy
Price Target: $6
Current: $4.49
Upside: +33.78%
Sep 30, 2025
Maintained: Buy
Price Target: $12
Current: $14.00
Upside: -14.29%
Oct 2, 2024
Rated: Buy
Price Target: n/a
Current: $6.44
Upside: n/a
Sep 16, 2024
Maintained: Buy
Price Target: n/a
Current: $4.81
Upside: n/a
Sep 2, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $1.83
Upside: n/a
May 5, 2021
Reiterated: Buy
Price Target: n/a
Current: $10.39
Upside: n/a